MRC Technology Archives

Home MRC Technology

Latest Posts

Interview 28 Sep 2017

Ethical Drug Development can Start with Charity Investors: A Conversation

As the furor over drug pricing has driven the biopharma industry to reflect on its ethics, I sat down with David Pardoe of LifeArc to discuss the involvement of charity…

September 28, 2017 - 6 minutesmins - By Evelyn Warner

News and Trends 15 Jun 2017

MRC Technology, now LifeArc, Set to Invest £500M in UK’s Life Sciences

LifeArc will draw funds from royalties of MSD's successful checkpoint inhibitor Keytruda to invest in life sciences in both academic and business sectors. Born from the UK's Medical Research Council,…

June 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

astrazeneca asthma copd epigenetic targets

News and Trends 21 Jun 2016

UK Partnership is looking for new Epigenetic targets in Respiratory Disease

AstraZeneca and MRC Technology are launching an initiative to find new epigenetic targets in respiratory disease. By picking promising academic research, the two parties expect to lock in new drugs…

June 21, 2016 - 2 minutesmins - By Denise Neves Gameiro

stevenage biosciences catalyst catapult appolo MRC biotech

News and Trends 19 Apr 2016

Drug Discovery moves to Stevenage – the new Golden Triangle hotspot?

MRC Technology, a UK medical research charity, has moved most of its labs to the Stevenage Bioscience Catalyst (SBC) campus. Located inside the gold triangle, is this the new hotspot of…

April 19, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 12 Jun 2015

MRC Technology and Peptinnovate partnered to cure bone diseases

MRC Technology and Peptinnovate teamed up to target bone diseases using peptides derived from the bacterium Mycobacterium tuberculosis. The partnership was created at Stevenage Bioscience Catalyst, a UK-based life sciences cluster. Natural…

June 12, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 11 Mar 2015

First Treatment Approved under Early Access to Medicine Scheme (EAMS)

Today, it has been accepted! The first drug approved through the Early Access to Medicine Scheme (EAMS), named pembrolizumab, is an immunotherapy treatment for advanced melanoma. The treatment has been developed…

March 11, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

The latest news on

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

Americas

Asia Pacific

Europe

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Company

Join Us

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering